New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 16, 2014
14:37 EDTICPTIntercept Phase 3 POISE trial of OCA meets primary endpoint
Intercept Pharmaceuticals announced that its international Phase 3 POISE trial of obeticholic acid. OCA, for the treatment of primary biliary cirrhosis, PBC, demonstrated that OCA, at both a 10 mg dose and a 5 mg dose titrated to 10 mg, met the trial's primary endpoint of achieving a reduction in serum alkaline phosphatase to < 1.67x ULN with a = 15% reduction from baseline and a normal bilirubin level after 12 months of therapy. The proportion of patients meeting the POISE primary endpoint was: 10% in the placebo group, 47% in the 10 mg OCA group and 46% in the 5-10 mg OCA group in an intention to treat analysis. In addition, both OCA dose groups met pre-specified secondary endpoints of improvements in other liver function parameters, including GGT, ALT, AST and total bilirubin. In order to evaluate the clinical relevance of the POISE primary endpoint, Intercept sponsored an independent study conducted by the Global PBC Study Group, consisting of 15 leading PBC centers in eight countries that contributed to a clinical outcomes database of more than 6,000 PBC patients. In this study, patients who did not achieve the POISE endpoint after one year were shown to have a greatly increased risk of liver transplant or death compared to those who achieved the endpoint. The PBC Supergroup has also previously confirmed that higher ALP levels in patients correlate with increased risk of liver transplant and death.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
05:44 EDTICPTIntercept FLINT trial data shows OCA treatment increases fibrosis resolution
Subscribe for More Information
April 22, 2015
07:07 EDTICPTEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
April 17, 2015
10:00 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:53 EDTICPTIntercept initiated with a Buy, $465 target at UBS
UBS analyst Matthew Roden started shares of Intercept Pharmaceuticals with a Buy rating and $465 price target. Roden sees a favorable risk/reward ahead of the approval and commercial launch of the company's obeticholic acid, known as OCA, in primary biliary cirrhosis. Roden also thinks OCA's opportunity in nonalcoholic steatohepatitis is being undervalued at current share levels. Shares of Intercept closed yesterday up $2.53 to $274.44.
April 13, 2015
08:24 EDTICPTDeutsche Bank pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
06:07 EDTICPTIntercept announces several presentations evaluating OCA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use